蝌蚪网

关注我们的社交群

A*STAR 新闻

新科研社交媒体平台

关注新科研的最新消息、观看我们的科学视频及其他更多精彩的内容等!

astar avatar waving


   

了解新科研

查看以下信息图表,欲知更多有关我们科学研发和技术创新.

A*STAR Stickers
下载新科研WhatsApp 张贴纸

下载新科研电报贴纸
新科研最新贴文

Announcement of ETC-206, A*STAR’s second publicly funded cancer drug

A*STAR’s second publicly funded cancer drug

Dr Kassoum Nacro- Research Project Leader- Medicinal Chemistry- ETC- A*STAR- and and the Inventor of ETC-206- explains the chemical make-up of ETC-206 in his lab.

ETC-206 is A*STAR’s second publicly-funded cancer drug to enter Phase 1 clinical trials- after ETC-159 in June 2015. ETC-206- which targets blood cancers- was discovered and developed through a collaboration between A*STAR’s Experimental Therapeutics Centre (ETC)- the Drug Discovery and Development (D3) unit- and Duke-National University of 蝌蚪网Medical School (Duke-NUS). It advanced into first-in-man trials in December 2016- with clinical research operations coordinated by the 蝌蚪网Clinical Research Institute (SCRI). The drug promises a more targeted approach to treating leukaemia and other forms of blood cancer- and could lower mortality rates for cancer compared to traditional chemotherapy which kills both healthy cells as well as cancer cells.